Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance
- 14 June 2006
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 61 (1) , 31-35
Abstract
Aims: Pancreatic adenocarcinoma is an aggressive gastrointestinal malignancy with only a few long-term survivors even after radical surgery. Patients with ampullary cancer have a better prognosis but adjuvant therapy needs further improvement. Epithelial cell adhesion molecule (Ep-CAM) is strongly expressed in a variety of epithelial cancers and represents a promising target for immunological tumour therapy. Thus, the aim of this study was to investigate Ep-CAM expression and its potential prognostic impact in pancreatic and ampullary carcinomas. Methods: Ep-CAM expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series of consecutive patients with pancreatic (n = 153) and ampullary cancer (n = 34). Results: Ep-CAM overexpression was observed in 85 of 153 pancreatic cancer specimens (56%) and in 29 of 34 ampullary cancer samples (85%). Overall, Ep-CAM failed to be an independent prognostic marker. However, subgroup analyses showed that Ep-CAM overexpression correlated with shorter overall survival among patients with ampullary cancer and advanced stage pancreatic cancer. In the latter subgroup, survival gradually worsened with increasing Ep-CAM scores. Furthermore, in ampullary cancer, Ep-CAM overexpression was found to correlate with tumour stage. Conclusions: Ep-CAM overexpression was detectable in the majority of cases with pancreatic and ampullary cancer. Therefore, Ep-CAM represents an attractive target for immune-based therapeutic interventions in these tumour entities. However, the prognostic value of Ep-CAM overexpression remains undetermined.Keywords
This publication has 23 references indexed in Scilit:
- Immunotherapy of malignant ascites with trifunctional antibodiesInternational Journal of Cancer, 2005
- Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesBritish Journal of Cancer, 2005
- High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast CancerBreast Cancer Research and Treatment, 2004
- The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferationOncogene, 2004
- In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatmentInternational Journal of Cancer, 2002
- A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrugBritish Journal of Cancer, 2002
- Ep-CAM overexpression in breast cancer as a predictor of survivalThe Lancet, 2000
- Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicatorsJournal of Gastrointestinal Surgery, 2000
- The expression of Ep-CAM (17-1 A)in squamous cell cancers of the lungHuman Pathology, 2000
- TNM classification of malignant tumors, fifth edition (1997)Cancer, 1997